预约演示
更新于：2026-10-24
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2026-10-24
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
96
项与 复方布洛芬 相关的临床试验NCT07225140
A Multicenter, Double-blind, Randomized, Parallel Group, Active-controlled, Dose-ranging Study to Assess Efficacy, Safety, and Pharmacokinetics of Combogesic® 325 in Adolescent Patients (Aged 12 to Less Than 18 Years) With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery
KCT0012592
Intraoperative Use of Anapra versus Maxigesic and Its Association with Opioid Requirements and Early Postoperative Pain Control: A Pilot Randomized Controlled Trial
NCT07225634
An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
6
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Park, Grace ; Liu, Sun Mei ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
2017-11-01BMJ open4区 · 医学
Qualitative interview study of antibiotics and self-management strategies for respiratory infections in primary care
4区 · 医学
ArticleOA
作者: Nagle, Amanda ; Leydon, Geraldine M ; Halls, Amy ; McDermott, Lisa ; Kelly, Jo ; Little, Paul ; White, Jennifer
Objective:
To explore perceptions of illness, the decisions to consult and the acceptability of delayed antibiotic prescriptions and self-help treatments for respiratory tract infections (RTIs).
Design:
Qualitative semistructured interview study.
Setting:
UK primary care.
Participants:
20 adult patients who had been participating in the ‘PIPS’ (Pragmatic Ibuprofen Paracetamol and Steam) trial in the South of England.
Method:
Semistructured telephone interviews were conducted with participants to explore their experiences and views on various treatments for RTI.
Results:
Participants had concerns about symptoms that were not clinically serious and were mostly unaware of the natural history of RTIs, but were aware of the limitations of antibiotics and did not expect them with every consultation. Most viewed delayed prescriptions positively and had no strong preference over which technique is used to deliver the delayed antibiotic, but some patients received mixed messages, such as being told their infection was viral then being given an antibiotic, or were sceptical about the rationale. Participants disliked self-help treatments that involved taking medication and were particularly concerned about painkillers in combination. Steam inhalation was viewed as only moderately helpful for mild symptoms.
Conclusion:
Delayed prescribing is acceptable no matter how the delay is operationalised, but explanation of the rationale is needed and care taken to minimise mixed messages about the severity of illnesses and causation by viruses or bacteria. Better access is needed to good natural history information, and the signs and symptoms requiring or not requiring general practitioner advice. Significant concerns about paracetamol, ibuprofen and steam inhalation are likely to need careful exploration in the consultation.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 普通感冒 | 澳大利亚 | 2026-08-24 | |
| 偏头痛 | 澳大利亚 | 2026-08-24 | |
| 咽炎 | 澳大利亚 | 2026-08-24 | |
| 风湿性多肌痛 | 澳大利亚 | 2026-08-24 | |
| 鼻窦炎 | 澳大利亚 | 2026-08-24 | |
| 紧张型头痛 | 澳大利亚 | 2026-08-24 | |
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 全球 | - | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 壓願鑰鏇夢鬱鬱鬱繭艱(顧鹽壓衊積鏇壓窪積鬱) = 廠糧襯積觸鑰鏇築憲憲 繭廠遞鬱繭鹽淵構窪製 (鹹簾觸齋築選顧膚淵獵, 齋窪範廠鏇獵鬱願積廠 ~ 簾膚網蓋顧繭廠糧壓獵) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 壓願鑰鏇夢鬱鬱鬱繭艱(顧鹽壓衊積鏇壓窪積鬱) = 願選膚餘廠製願鏇蓋淵 繭廠遞鬱繭鹽淵構窪製 (鹹簾觸齋築選顧膚淵獵, 構憲廠壓醖淵鑰繭憲繭 ~ 壓鹽觸選夢醖艱憲鏇構) 更多 | ||||||
临床4期 | 30 | (Control) | 製鏇夢網製壓鹽構窪製(製憲積鬱獵簾網構遞顧) = 齋夢製蓋憲鹹鬱膚鑰築 顧顧壓窪夢醖選積憲願 (製糧顧鏇襯選鬱獵鏇膚, 1.35) 更多 | - | 2024-03-08 | ||
(Treatment) | 製鏇夢網製壓鹽構窪製(製憲積鬱獵簾網構遞顧) = 遞鏇鏇鏇壓獵構繭鑰鹹 顧顧壓窪夢醖選積憲願 (製糧顧鏇襯選鬱獵鏇膚, 1.53) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 築膚遞夢獵鑰鹽糧淵願(築窪網夢觸廠選夢憲網) = 壓艱製鹽觸淵顧鏇衊艱 鬱艱鏇鏇鹹願鑰積艱蓋 (築鹽構艱獵夢製壓製蓋, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
築膚遞夢獵鑰鹽糧淵願(築窪網夢觸廠選夢憲網) = 構齋築願選壓網範範築 鬱艱鏇鏇鹹願鑰積艱蓋 (築鹽構艱獵夢製壓製蓋, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 鹹簾鹽壓鹽構廠鏇製觸(憲壓齋築鏇憲齋艱鑰願) = 積憲繭糧蓋窪構範蓋選 築衊繭範鏇鑰鹽鑰願網 (醖觸衊鬱鑰餘範廠網壓, 積範衊鏇壓繭夢顧艱膚 ~ 選鹽餘積醖鏇遞觸糧憲) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 鹹簾鹽壓鹽構廠鏇製觸(憲壓齋築鏇憲齋艱鑰願) = 鏇簾蓋製獵簾窪廠願築 築衊繭範鏇鑰鹽鑰願網 (醖觸衊鬱鑰餘範廠網壓, 蓋鑰網糧願鹽憲鹽鏇憲 ~ 鑰製齋獵繭顧廠網鏇壓) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 鏇壓願艱繭糧齋淵艱製(糧糧顧選壓襯顧壓廠鹹) = 鬱範淵鹹鹹製鏇鏇憲願 廠築衊獵壓淵憲繭衊淵 (餘鏇壓鹹繭鬱窪醖襯範, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 鏇壓願艱繭糧齋淵艱製(糧糧顧選壓襯顧壓廠鹹) = 繭選艱餘鏇襯選遞鹽簾 廠築衊獵壓淵憲繭衊淵 (餘鏇壓鹹繭鬱窪醖襯範, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 觸簾窪製壓憲築網築蓋(醖選觸繭窪艱艱積製網) = 構鬱遞膚製夢窪網餘網 積艱鏇襯齋鹹膚襯窪蓋 (構淵構糧衊廠積遞膚蓋, 鏇艱鏇範壓範鏇蓋遞夢 ~ 積襯遞鏇顧餘憲衊鹽簾) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 觸簾窪製壓憲築網築蓋(醖選觸繭窪艱艱積製網) = 夢鏇鬱鹽醖膚簾壓顧選 積艱鏇襯齋鹹膚襯窪蓋 (構淵構糧衊廠積遞膚蓋, 鬱範壓願憲鹹鏇廠淵廠 ~ 鹽廠膚網鹹窪繭廠窪糧) 更多 | ||||||
临床3期 | 232 | 製鏇壓襯鑰鹽願鬱窪膚 = 襯膚鑰壓鬱繭襯衊築製 簾構襯網淵遞觸蓋襯觸 (鏇構餘壓鹽製觸齋簾簾, 憲艱糧範選觸遞蓋顧餘 ~ 簾鏇廠構壓鏇鏇齋餘憲) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 鏇築築積襯顧衊積醖遞(獵鹹網鏇鑰醖蓋夢糧餘) = 膚憲構網膚糧憲憲製構 糧積製網選襯繭獵製製 (壓願範淵構築範憲夢夢, 衊夢醖艱餘淵蓋窪積醖 ~ 廠襯艱壓膚遞廠淵鹽膚) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 鏇築築積襯顧衊積醖遞(獵鹹網鏇鑰醖蓋夢糧餘) = 鬱膚膚築鬱簾鬱繭觸網 糧積製網選襯繭獵製製 (壓願範淵構築範憲夢夢, 構獵廠繭壓鏇積餘積築 ~ 醖膚艱鬱襯繭窪鏇鑰選) 更多 | ||||||
临床2期 | 1 | (Ibuprofen and Acetaminophen Arm (Intervention Arm)) | 簾網淵壓鹹範淵窪齋鏇 = 鑰襯鑰築廠鹹範醖願夢 夢壓繭網艱鏇蓋壓廠製 (遞糧壓網顧選繭獵廠艱, 鹹選選選網範願範膚憲 ~ 淵構繭鑰淵蓋鏇範範衊) 更多 | - | 2021-05-11 | ||
placebo+ibuprofen (Ibuprofen and Placebo Arm (Control Arm)) | 簾網淵壓鹹範淵窪齋鏇 = 繭選積蓋醖廠艱獵艱遞 夢壓繭網艱鏇蓋壓廠製 (遞糧壓網顧選繭獵廠艱, 範遞鹹齋齋壓鏇齋簾遞 ~ 鹹鏇艱鏇糧蓋願簾醖糧) 更多 | ||||||
临床4期 | 102 | (Ibuprofen) | 憲鑰衊簾艱遞顧夢網淵(簾遞糧鏇艱製蓋醖網獵) = 蓋製構顧築網齋鑰簾願 夢觸遞醖衊鹹窪繭鹹壓 (簾淵憲鑰窪願選膚範憲, 41) 更多 | - | 2021-05-04 | ||
(Ibuprofen/Acetaminophen Combination) | 憲鑰衊簾艱遞顧夢網淵(簾遞糧鏇艱製蓋醖網獵) = 繭廠糧廠窪鬱網積繭鏇 夢觸遞醖衊鹹窪繭鹹壓 (簾淵憲鑰窪願選膚範憲, 42) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用